Dear Editor,
We read with great interest the article by Yarlagadda et al., which demonstrated a significant reduction in contralateral submandibular gland (SMG) mean dose (32.92 Gy vs. 20.22 Gy, p < 0.001) following SMG transfer in oropharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) [1]. While the dosimetric findings are encouraging, we wish to raise three critical concerns regarding the study's methodology and clinical interpretation.
First, the title and conclusion claim that SMG transfer “preserves salivary function,” yet the study provides no functional data-neither objective salivary flow rates nor patient-reported xerostomia outcomes [1]. The authors themselves acknowledge this limitation, stating that “clinical salivary function outcomes were not available for this cohort” [1]. While the dose-response relationship established by Murdoch-Kinch et al. [2] supports the biological plausibility of dose reduction, it does not eliminate the need for direct clinical validation. Without functional endpoints, the clinical significance of a 12.02 Gy mean dose reduction remains speculative.
Second, the study lacks a control group of patients treated with IMPT without SMG transfer. The within-patient comparison (pre- vs. post-transfer plans) cannot establish whether the observed dose reduction translates into a clinically meaningful advantage over standard proton planning. Previous phase II studies [3] have demonstrated that SMG transfer provides functional benefit in the 2D/3D era, but whether this holds true with modern IMPT-which already achieves excellent parotid and SMG sparing-remains unproven. The authors' own prior work with IMRT [4] showed no dosimetric benefit with SMG transfer, highlighting the need for comparative data.
Third, the comparison suffers from re-optimization bias. The post-transfer plan was specifically re-optimized to spare the gland in its new location, whereas the pre-transfer plan was not re-optimized with the same intent for the original gland position [1]. To isolate the true effect of transfer, a second re-optimized plan assuming the gland remained in its original position would have been necessary. This distinction is critical, as modern IMPT optimization alone might achieve similar sparing without surgery.
Additionally, the small sample size (n = 17) and absence of a priori power calculation limit generalizability, and potential inter-fraction gland motion during 6–7 weeks of radiotherapy is not addressed.
We agree with the authors that “future prospective trials incorporating patient-reported outcomes and objective salivary flow assessments will be essential” [1]. However, we believe that the current study, while a valuable pilot, stops short of demonstrating clinical benefit. We respectfully suggest that functional outcomes from this cohort be provided, or that a prospective comparative trial be designed to clarify the role of SMG transfer in the IMPT era.
We thank the authors for their important contribution and look forward to their response.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- 1.Yarlagadda S., Young G.D., Rohe R.M., McNeill V., Nemec J.R., Tohtz C.P., et al. Integrating submandibular gland transfer with proton therapy to preserve salivary function. Clin Transl Radiat Oncol. 2026;61 doi: 10.1016/j.ctro.2026.101269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Walters R., Kutuk T., Williams A., Rosen E.B., Contreras J., Coutinho L., et al. Proton therapy specific salivary gland volume changes after head and neck radiotherapy. Int J Radiat Oncol Biol Phys. 2021;111(3) doi: 10.1016/j.ijrobp.2021.07.1033. [DOI] [Google Scholar]
- 3.Kutuk T., McAllister N.C., Rzepczynski A.E., Williams A., Young G., Crawley M.B., et al. Submandibular gland transfer for the prevention of radiation-induced xerostomia in oropharyngeal cancer: dosimetric impact in the intensity modulated radiotherapy era. Head Neck. 2022;44(5):1213–1222. doi: 10.1002/hed.27021. [DOI] [PubMed] [Google Scholar]
- 4.Shuman A.G., Li D., Singh R., Li M., Shoushtari A., Raad R., et al. Relationship between clinician-measured health outcomes and patient-reported outcomes following head and neck radiation therapy. Tech Innov Patient Support Radiat Oncol. 2023;25 doi: 10.1016/j.tipsro.2022.11.001. [DOI] [Google Scholar]
